{"The": [0, 27, 150], "latest": [1], "severe": [2], "acute": [3], "respiratory": [4], "syndrome": [5], "coronavirus": [6], "2": [7], "(SARS-CoV-2)": [8], "variant": [9, 36], "Omicron": [10, 56, 104, 140, 167], "(B.1.1.529)": [11], "has": [12, 84], "ushered": [13], "panic": [14], "responses": [15], "around": [16], "the": [17, 34, 43, 113, 123, 127, 171, 202], "world": [18], "due": [19], "to": [20, 146, 191, 200], "its": [21, 40, 185], "contagious": [22, 111], "and": [23, 30, 75, 94, 153, 181, 208], "vaccine": [24, 73], "escape": [25, 147], "mutations.": [26], "essential": [28], "infectivity": [29], "antibody": [31, 76], "resistance": [32], "of": [33, 55, 70, 89, 91, 129, 134, 173], "SARS-CoV-2": [35, 206], "are": [37], "determined": [38], "by": [39, 97], "mutations": [41], "on": [42, 100, 187], "spike": [44], "(S)": [45], "protein": [46], "receptor-binding": [47], "domain": [48], "(RBD).": [49], "However,": [50, 184], "a": [51, 66], "complete": [52], "experimental": [53, 92, 98], "evaluation": [54], "might": [57], "take": [58], "weeks": [59], "or": [60, 116], "even": [61], "months.": [62], "Here,": [63], "we": [64, 137], "present": [65], "comprehensive": [67], "quantitative": [68], "analysis": [69], "Omicron's": [71], "infectivity,": [72], "breakthrough,": [74], "resistance.": [77], "An": [78], "artificial": [79], "intelligence": [80], "(AI)": [81], "model,": [82], "which": [83], "been": [85], "trained": [86], "with": [87], "tens": [88], "thousands": [90], "data": [93], "extensively": [95], "validated": [96], "results": [99], "SARS-CoV-2,": [101], "reveals": [102], "that": [103, 139], "may": [105, 141, 163, 168], "be": [106, 164, 192], "over": [107], "10": [108], "times": [109, 119], "more": [110], "than": [112], "original": [114], "virus": [115], "about": [117], "2.8": [118], "as": [120, 122], "infectious": [121], "Delta": [124], "variant.": [125], "On": [126], "basis": [128], "185": [130], "three-dimensional": [131], "(3D)": [132], "structures": [133], "antibody-RBD": [135], "complexes,": [136], "unveil": [138], "have": [142], "an": [143], "88%": [144], "likelihood": [145], "current": [148], "vaccines.": [149], "U.S.": [151], "Food": [152], "Drug": [154], "Administration": [155], "(FDA)-approved": [156], "monoclonal": [157], "antibodies": [158], "(mAbs)": [159], "from": [160, 175], "Eli": [161], "Lilly": [162], "seriously": [165], "compromised.": [166], "also": [169], "diminish": [170], "efficacy": [172], "mAbs": [174], "AstraZeneca,": [176], "Regeneron": [177], "mAb": [178], "cocktail,": [179], "Celltrion,": [180], "Rockefeller": [182], "University.": [183], "impacts": [186], "GlaxoSmithKline's": [188], "sotrovimab": [189], "appear": [190], "mild.": [193], "Our": [194], "work": [195], "calls": [196], "for": [197], "new": [198], "strategies": [199], "develop": [201], "next": [203], "generation": [204], "mutation-proof": [205], "vaccines": [207], "antibodies.": [209]}